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BACKGROUND: The ERG oncogene, a member of the ETS family of transcription factor 
encoding genes, is a genetic driver of prostate cancer. It is activated through a fusion with 
the androgen-responsive TMPRSS2 promoter in 50% of cases. There is therefore significant 
interest in developing novel therapeutic agents that target ERG. We have taken an antisense 
approach and designed morpholino-based oligonucleotides that target ERG by inducing 
skipping of its constitutive exon 4.   
METHODS: We designed antisense morpholino oligonucleotides (splice-switching 
oligonucleotides, SSOs) that target both the 5′ and 3′ splice sites of ERG’s exon 4. We tested 
their efficacy in terms of inducing exon 4 skipping in two ERG-positive cell lines, VCaP 
prostate cancer cells and MG63 osteosarcoma cells. We measured their effect on cell 
proliferation, migration and apoptosis. We also tested their effect on xenograft tumour 
growth in mice and on ERG protein expression in a human prostate cancer radical 
prostatectomy sample ex vivo. 
RESULTS: In VCaP cells, both SSOs were effective at inducing exon 4 skipping, which resulted 
in a reduction of overall ERG protein levels up to 96 hours following a single transfection. 
SSO-induced ERG reduction decreased cell proliferation, cell migration and significantly 
increased apoptosis. We observed a concomitant reduction in protein levels for cyclin D1, c-
Myc and the Wnt signalling pathway member β-catenin as well as a marker of activated Wnt 
signalling, p-LRP6. We tested the 3′ splice site SSO in MG63 xenografts in mice and observed 
a reduction in tumour growth. We also demonstrated that the 3′ splice site SSO caused a 
reduction in ERG expression in a patient-derived prostate tumour tissue cultured ex vivo. 
CONCLUSIONS: We have successfully designed and tested morpholino-based SSOs that 
cause a marked reduction in ERG expression, resulting in decreased cell proliferation, a 
reduced migratory phenotype and increased apoptosis. Our initial tests on mouse 
xenografts and a human prostate cancer radical prostatectomy specimen indicate that SSOs 
can be effective for oncogene targeting in vivo. As such, this study encourages further in 
vivo therapeutic studies using SSOs targeting the ERG oncogene.   
BACKGROUND 
 
The human oncogene ETS-related gene (ERG), located on chromosome 21, encodes an E-26 
transformation-specific (ETS) family of DNA-binding transcription factors. There are at least 
28 ETS family members in humans, involved in a wide range of developmental processes1. 
All members of the family share a conserved 85 amino-acid region known as the ETS DNA-
binding domain that recognises a target sequence containing a core GGA(A/T) motif2. The 
ETS member ERG was first described in 1987 by Rao et al3. The ERG oncogene is now 
considered an oncogenic driver in prostate cancer (PCa)4,5. ERG is over-expressed in a 
remarkable 50% of PCa cases because of a 3Mb deletion that fuses the androgen-responsive 
TMPRSS2 promoter with ERG6. The fusion most often occurs between TMPRSS2 exons 1 or 2 
and exon 4 of ERG4. We have recently shown that ERG expression is increased in patients 
with advanced PCa and that higher levels of ERG are associated with seminal vesicle 
invasion (stage T3b) and biochemical recurrence7 (prostate-specific antigen (PSA)–only 
recurrence).  
Recent literature has continued to underline ERG’s important role in PCa. The list of 
oncologically significant transcriptional targets of ERG is growing. These now include the 
Wnt receptor Frizzled 8 (FZD8)8, the tumour suppressor phosphatase and tensin homologue 
(PTEN)9, and the α1 and β1 subunits of soluble guanylyl cycles (GUCY1A3 and GUCY1B3)10, 
the latter indicating that TMPRSS2:ERG can activate NO-cGMP signalling in PCa. 
TMPRSS2:ERG also enhances the osteoblastic phenotype of PCa bone metastases11 and 
promotes the recruitment of regulatory T cells to promote tumour growth12. In addition to 
its increasing prominence in PCa, it is also clear that ERG exerts its oncogenic effects in 
other contexts. For example, ERG has been described as a megakaryocytic oncogene that 
promotes the rapid onset of leukemia in mice13. Additional complexity in ERG’s oncogenic 
properties arises from alternative splicing. The majority of human multi-exon genes are 
alternatively spliced including ERG. Of particular interest is ERG’s cassette exon 7b. Exon 7b 
is 72 bp long and adds, in-frame, 24 amino-acids to the transcriptional transactivation 
domain. We have shown that increased exon 7b inclusion is associated with advanced PCa7. 
The 24 amino-acids encoded by the evolutionarily-conserved exon 7b include an 
extracellular-signal-regulated kinase (ERK) docking site (with consensus sequence FxFP)14. 
The functional importance of the ERK docking motif encoded by exon 7b is now clear. The 
phosphorylation of ERG by ERK leads to the dissociation of Polycomb repressive complex 2 
(PRC2) resulting in ERG target gene activation. Mutation of the ERK docking site to AAAP 
prevents phosphorylation of ERG by ERK15. In our hands, and consistent with these findings, 
the reduction of exon 7b inclusion induced with splice-switching oligonucleotides (SSOs) 
resulted in decreased cell proliferation, migration and increased apoptosis14 confirming that 
exon 7b contributes to ERG’s oncogenic properties. These findings are consistent with 
earlier observations by Wang and colleagues who demonstrated that ERG isoforms that 
include 7b are more efficient in driving cell proliferation 16.  
Given the growing importance of ERG in PCa there is widespread interest in 
developing ERG-based therapies. One approach is to target co-factors of ERG such as poly 
ADP-ribose polymerase (PARP) and histone deacetylase (HDAC). Treatment with the PARP 
inhibitor olaparib reduces the invasive properties of ERG-positive cells17 and another PARP 
inhibitor, rucaparib, sensitises cells to low-dose radiation18. Treatment of ERG-positive cells 
with the HDAC inhibitors trichostatin A and MS-275 reduces cell growth and increases cell 
death19. Another approach is to target the ERG transcription factor directly20. The small 
molecule inhibitor YK-4-279 binds to ERG, interferes with its protein-protein interactions 
inhibiting its transcriptional activity21, and impedes the growth of patient-derived PCa 
xenografts in mice22. Cancer-associated genes can also be targeted with antisense 
oligonucleotides (ASOs)23,24. The pharmacodynamic properties of ASOs are improving 
significantly and there is a wide choice of chemistries available25. Among these, morpholinos 
are highly stable DNA analogues, which provide excellent results in vivo26 as illustrated by 
the FDA-approved morpholino drug Eteplirsen (Exondys 51, Sarepta Therapeutics Inc.), 
designed for the treatment of the effects of mutations that cause Duchenne’s muscular 
dystrophy (DMD), a previously intractable genetic degenerative muscle disease. Eteplirsen 
functions by causing the skipping of exon 51 of the DMD transcript and is proving to be 
clinically effective27. ASOs can modify target gene expression in several ways28. They can 
bind proximally to the translation start site and impede translation and in the case of SSOs, 
they can also interfere with pre-mRNA splicing. SSOs can promote the inclusion of desirable 
exons (e.g. TOES, targeted oligonucleotide enhancers of splicing29), or induce exon skipping 
as illustrated by our own ERG exon 7b SSO14 and Eteplirsen27. Another success story is 
Nusinersen, an FDA-approved ASO (Spinraza, Biogen) that is used to treat spinal muscular 
atrophy (SMA). It alters survival motor neuron 2 (SMN2) pre-mRNA splicing to restore 
inclusion of a mutated exon 7, increasing the expression of functional SMN protein. Spinraza 
achieves improved motor milestones and event-free survival in children with this previously 
intractable genetic condition30. 
Here we describe the first study to design and evaluate morpholino-based SSOs that 
target ERG’s exon 4. We test their effect on ERG protein expression and cancer cell biology 
in ERG-expressing cell lines, and their effect on tumour growth in xenografted mice and 
their ability to disrupt ERG expression ex vivo. 
 
 
METHODS 
Cell culture 
MG63 (ECACC, human osteoblast-like osteosarcoma cells, catalogue no. 86051601) and 
VCaP cells (ECACC, human prostate cancer vertebral metastasis, catalogue no. 06020201) 
were grown in DMEM (Gibco, UK) supplemented with 10% (v/v) fetal bovine serum (Sigma-
Aldrich, UK) and 2 mM glutamine at 37 °C, in a 5% CO2 humidified incubator. 
 
Vivo morpholinos 
All vivo-morpholino splice-switching oligonucleotides (SSOs) were purchased from Gene 
Tools, LLC, USA. SSOs were designed against both the 5′ and 3′ splice-sites of ERG exon 4. 
The sequence of the ERG exon 4 5′ splice-site-targeting SSO (E45′) was 5′-
GGCGGAAGTCTCCTTACCTTGAGCC-3′ and for the ERG exon 4 3′ splice-site (E43′) the SSO 
sequence was 5′-GCTTCCTGAATGCCCAAAGAAACAC-3′. The sequence for the control SSO in 
vitro, targeting an intron in a ß-globin gene variant associated with ß-thalassaemia was 5′-
CCTCTTACCTCATTACAATTTATA-3′. For in vivo and ex vivo experiments, the sequence for the 
scrambled control SSO was 5′-GACAATATAGGACGCCACCGCAACC-3′. Stocks of each vivo 
morpholino were prepared in sterile tissue culture grade H2O (Gibco, UK) at a concentration 
of 0.5 mM. Each SSO had an octa-guanidine dendrimer moiety to facilitate delivery for 
cellular uptake and was added directly to culture media. For experiments with VCaPs, the 
transfection reagent endoporter (Gene Tools, LLC, USA) was used at 10 μM to facilitate the 
uptake of SSOs. The Gene Tools recommended working concentration range for vivo-
morpholinos in cell culture is 1-10 μM; we therefore performed experiments within this 
range.  
 
RNA extraction, cDNA synthesis and PCR 
For in vitro experiments, total RNA was extracted using a total RNA isolation mini kit (Agilent 
Technologies Ltd) according to manufacturer’s instructions. All samples were treated with 
DNAse on the columns using RNase-free DNase I provided in the kit. For in vivo and ex vivo 
experiments, total RNA was extracted using mechanical homogenisation of samples with 
Qiazol (Qiagen) according to manufacturer instructions. cDNA was synthesised from 0.2-1 
μg of total RNA using a Precision nanoScript 2 Reverse transcription kit (Primerdesign Ltd, 
UK), according to manufacturer instructions. 
 Hot Start Taq 2X master mix (New England Biolabs (NEB), UK) was used for standard 
PCR according to manufacturer instructions. Primers for detecting ERG exon 4 skipping were 
as follows, forward: 5′-TTTGGAGACCCGAGGAAAGC-3′, reverse: 5′-
AGAGAAGGATGTCGGCGTTG-3′. The final concentration for each primer in the reaction was 
0.4 μM. PCRs were run as follows: initial denaturation at 95 °C for 30 seconds, then 30 
cycles of 95 °C for 30 seconds, 54 °C for 1 minute, 68 °C for 1 minute and a final extension at 
68 °C for 5 minutes. 
Gels were imaged on a Li-Cor Odyssey Fc imaging system (Li-Cor Ltd). Splice isoform 
ratios were determined by measuring the relative brightness of PCR bands compared to 
each other using gel Image Studio Lite software (Li-Cor Ltd). Percent spliced in (PSI) was 
determined as a ratio of the intensity of the top band (exon included) to the total signal of 
both bands. Following imaging, PCR bands were excised using a Monarch DNA Gel 
Extraction Kit (NEB) according to manufacturer’s instructions and exon skipping was 
confirmed by sequencing with Eurofins Scientific (Germany). Sequences from Eurofins were 
aligned with ERG exon 4 reference sequences from NCBI (NIH) using ApE plasmid editor v2. 
 
Western blotting 
Lysates were prepared using RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% (v/v) 
Triton X-100, 0.1% (w/v) sodium deoxycholate, 0.1% (w/v) SDS and 140 mM NaCl) 
supplemented with protease inhibitor tablets (ThermoFisher, UK). Equal protein samples 
were separated on 10% (v/v) SDS polyacrylamide gel electrophoresis gels and transferred to 
PVDF membranes (Sigma Aldrich) which were blocked and probed overnight at 4 °C with 
1:1000 anti-ERG (Abcam, UK), 1:10,000 anti-β-actin (Abcam), 1:2500 anti-GAPDH (Millipore, 
UK), 1:1000 β-catenin, 1:1000 anti-c-Myc, 1:1000 anti-cyclin D1 or 1:1000 anti-phospho-
LRP6 (all Cell Signalling Technologies, UK) primary antibodies. Membranes were incubated 
in 1:2000 HRP-linked anti-rabbit or anti-mouse IgG secondary antibody (NEB) for 2 h at 
room temperature. Membranes were incubated in Luminata Forte Western HRP substrate 
(Millipore) for chemiluminescent detection prior to image acquisition using a Li-Cor Odyssey 
imaging system. 
 
Analysis of cell proliferation and apoptosis 
For proliferation and apoptosis assays cells were seeded on coverslips in 6-well plates and 
treated with SSOs for 48-96 h. To analyse proliferation, SSO-treated cells were fixed in 4% 
(v/v) PFA for 15 minutes and permeabilised with 0.1% (v/v) Triton X-100 followed by 
blocking in 3% (v/v) FBS for 1 h. Cells were incubated with rabbit Ki67 primary antibody 
(Abcam) in blocking solution (1:200) for 2 h at room temperature followed by incubation for 
1 h in 1:200 AlexaFluor 568 (ThermoFisher). For apoptosis assays, 45 minutes prior to the 
end of the SSO incubation period, CellEvent Caspase-3/7 reagent was added according to 
manufacturer instructions. For both assays, cells were counterstained in 2 μg/ml Hoechst 
3342, mounted in mowiol (Sigma Aldrich) and representative images were taken using an 
Eclipse 80i microscope (Nikon). ImageJ (v2.0-rc-69/1.52i) software was used to calculate the 
percentage of Ki67+ and Caspase-3/7+ cells. 
 
CD31 immunofluorescence  
Frozen sections from xenograft tumours were cut as 7 µm thick sections and fixed in 4% 
paraformaldehyde solution in PBS (ThermoFisher) for 10 minutes at room temperature. 
Fixed tumour tissues were washed in TBS and permeabilised with TBS with Triton X-100 
(TBS/T, 0.1% v/v) for 30 minutes at room temperature. Tissues were blocked with 10% 
normal goat serum (NGS) in 1% BSA in TBS/T for 1 hour at room temperature before 
incubating with rabbit anti-CD31 antibody (Abcam) diluted 1:50 in 1% BSA in TBS/T, 
overnight at 4 °C. Sections were washed in TBS/T and incubated with Alexafluor 568 goat 
anti-rabbit antibody (ThermoFisher) at 1:750 dilution in 1% BSA in TBS/T for one hour at 
room temperature. Sections were washed with TBS and mounted with mounting medium 
with DAPI (Abcam). Images were taken at 20x magnification with Leica DM4000 B LED 
Fluorescence microscope. 
  
Cell migration assays 
For migration assays, PET inserts (8 μm membrane pore size; Millipore) were placed in 24-
well plates and 1 x 105 of 24 h SSO-treated cells were added to the upper chamber of the 
insert in serum free media. 600 μl of medium with 10% (v/v) FBS was added to the lower 
chamber of the 24-well plate and cells were incubated for 48h. Cells remaining on the upper 
membrane of the insert were removed and inserts were fixed in 4% (v/v) PFA followed by 
staining with Hoechst for quantifying migrated VCaP cells. The inserts were imaged with an 
Eclipse 80i microscope and the number of cells present on the lower membrane of the 
inserts was quantified with ImageJ. For quantifying migrated MG63 cells, inserts were PFA 
fixed and stained using 0.2% (v/v) crystal violet in 2% (v/v) methanol. Inserts were then 
placed into 0.1% (v/v) SDS in PBS and the crystal violet residue in the SDS-PBS was 
quantified by transferring to a 96-well plate and measuring absorbance at 590nm. 
 
TopFlash luciferase reporter assays 
MG63 and VCaP cells were seeded in 6-well plates at a density of 500,000 cells per well in 
1.5 ml of medium. Cells were transfected with a cocktail of the following plasmids: 1 µg 
TopFlash and 50 ng pRL-TK using Lipofectamine 2000 (Invitrogen). After 24 hours, cells were 
trypsinised and seeded in 96-well plates at a density of 10,000 cells per well in 100 µM of 
medium. After 24 hours, SSOs were diluted in media supplemented with endoporter (Gene 
Tools), then added to the cells with final concentrations of 0.1, 0.3, 1.0, 3.0 and 10.0 µM, in 
triplicates. Following 24 hours of incubation, luciferase reporter activity was measured using 
the Dual-Glo system (Promega) on a plate reader. Relative luciferase activity was normalised 
to non-SSO controls.  
 
Mouse xenograft analysis 
Two-month-old male nude mice (CD1; Charles River, USA) were housed under pathogen-
free conditions. All animal operations were approved by the Animal Ethics Committee, 
University of Exeter, U.K. For heterotopic xenografts, 7 x 106 MG63 cells resuspended in 100 
μl of PBS were injected subcutaneously into the right flank of mice. Tumours were 
measured by caliper twice weekly and tumour volume was calculated according to the 
formula: [(length+width)/2]*length*width. Once tumours reached 3 mm by 3 mm in size, 
mice were randomly assigned to treatment groups so that combined tumour volumes were 
equivalent between groups. 12.5 mg/kg of either SSO (in PBS) or PBS alone was 
administered by intraperitoneal (I.P.) injection twice weekly, for each mouse in the morning 
in home cages, for the duration of the study (56 days). Systemic delivery was chosen since it 
more accurately reflects delivery methods likely to be applied in the clinic. Following the 
study, mice were euthanised by schedule 1 cervical dislocation and tumours were harvested 
for RNA and protein extraction. 
 
Ex vivo analysis 
Tissue sampling from radical prostatectomy specimens was performed using the PEOPLE 
methodology31 and ex vivo culture of tissue was performed as previously described32. 
Briefly, gelatin sponges were placed in 24-well plates with 200 μl of RPMI supplemented 
with 10% (v/v) FBS 2-3 h prior to tissue harvest to allow the sponges to draw up the media. 
For treatment groups, 10 μM SSO was added to the RPMI. Fresh 6 mm cores were divided 
using a scalpel and placed on the sponges, then incubated for up to 72 h followed by 
harvesting for histology and RNA/protein extraction as described above. For histological 
analysis, samples were fixed in 10% (v/v) neutral buffered formalin and stored as FFPE 
blocks. 4 μm sections from the FFPE blocks were stained with haematoxylin and eosin (H&E) 
to assess tumour content of samples as per the 100,000 Genomes Project standard 
operating procedures (https://www.genomicsengland.co.uk/about-genomics-england/the-
100000-genomes-project/information-for-gmc-staff/sample-handling-guidance). Slides 
were assessed by an experienced consultant uropathologist and tumour content was 
reported as 0-100% in 5% increments. For ERG immunohistochemistry, 4 μm sections from 
the FFPE blocks were stained on the BondMax autostainer (Leica) with anti-ERG antibody 
(Abcam, ab92513; 1:200 dilution). 
 
 
Statistical analysis 
ANOVAs (with Dunnet's tests where appropriate) or T-tests were carried out using 
GraphPad Prism 8 software. Significance levels are indicated by asterisks where * = P < 0.05, 
** = P < 0.01, and *** = P < 0.001 and are based on comparisons with untreated controls 
unless stated otherwise. Data are reported as means and error bars show 95% confidence 
intervals of means. 
 
RESULTS 
SSOs targeting ERG cause exon 4 skipping and a reduction in ERG protein levels in ERG-
positive cancer cells 
To investigate whether we could disrupt pre-mRNA splicing of the ERG oncogene in the 
context of prostate cancer (PCa), we first designed SSOs targeting the 3′ (E43′) and 5′ (E45′) 
splice-sites of exon 4 of ERG (Fig. 1a, Supplementary Fig. 1a). Exon 4 is 218 bp in size, and its 
skipping results in a frame-shift and premature termination codon (PTC) leading to 
nonsense-mediated decay (NMD) of the transcript. Specifically, if exon 4 is skipped, the 
frameshift produces a stop codon nine bases into exon 5, so that only 20 amino-acids of ERG 
are translated (MIQTVPDPAAHIKEALSELSstop, where the amino-acids ELS are provided by a 
frameshifted exon 5). Therefore, even if a proportion of exon 4-skipped mRNA escapes NMD 
and is translated, no viable ERG protein is produced. We treated the VCaP PCa cell line with 
a single dose of either the E43′ or E45′ SSOs and observed that both SSOs could cause 
skipping of exon 4 in ERG mRNA as assessed by reverse-transcription PCR (RT-PCR) from as 
early as 24 h up to 72 h following dosing (Fig. 1b, c). Additionally, for both SSOs we observed 
a dose-dependent effect on exon 4 skipping with increasing dose from 6-8 μM (Fig. 1b). By 
quantifying percentage spliced in (PSI) as a measure of exon 4 skipping, the E43′ SSO 
appeared more efficient at causing exon 4 skipping, as PSI values for the E43′ SSO were 
consistently lower than the E45′ SSO and significantly lower versus untreated and control 
SSO-treated cells from 24-72 h (Fig. 1d). We confirmed the skipping of exon 4 in both E43′ 
and E45′ SSO-treated PCR products by sequencing (Supplementary Fig. 1b). Since we 
observed partial but significant skipping of exon 4 at 8 μM doses and minimal cell toxicity 
(some toxicity was observed at 10 μM, data not shown), we proceeded with this dose for 
subsequent cell biology assays. 
 We next asked whether these SSO-induced changes in ERG at the mRNA level 
resulted in changes at the protein level. Western blotting demonstrated that at 24 h after 
E43′ and E45′ SSO treatment, ERG levels were largely unchanged (Fig. 2a, b). However, by 72 
h following SSO transfection, VCaP cells displayed clearly reduced ERG protein levels; by 96 
h ERG levels were even lower (Fig. 2a, b).  As expected, there was a time lag between SSO 
transfection and NMD of ERG mRNA and subsequent depletion of ERG protein; and the 
effect of a single SSO transfection on ERG expression persisted over several days. We 
confirmed these findings using another ERG-positive cancer cell line, the MG63 
osteosarcoma cell line. We obtained a similar result when treating MG63 cells with single 
doses of E43′ and E45′ SSOs, with more efficient skipping of exon 4 induced by the E43′ SSO 
(Fig. 2c, d). We therefore examined ERG protein levels in MG63 cells treated with the more 
efficient E43′ SSO and observed a significant reduction in ERG level by 72 h (Fig. 2e, f). Taken 
together, these results suggest that the use of ERG-targeting SSOs is a viable approach for 
reducing ERG protein expression in multiple cancer cell lines. 
 
SSOs targeting ERG affect PCa cell biology via down-regulation of Wnt/β-catenin signaling 
Over-expression of ERG in PCa is associated with disease initiation, progression and spread4. 
This ERG over-expression leads to downstream signalling that drives PCa cell proliferation, 
survival, migration and metastasis. We examined several of these cancer cell hallmarks 
following treatment of VCaP cells with single SSO doses and observed a significant reduction 
in VCaP cell proliferation in SSO-treated cells 48-96 h following dosing as assessed by Ki67 
staining (Fig. 3a, b). In support of this, we found that the cell cycle regulator cyclin D1 
appeared downregulated following SSO transfection (Fig. 3c). Interestingly, we observed 
that expression of c-Myc, a potent regulator of cellular proliferation33, which has been 
shown to be activated by TMPRSS2-ERG fusions in PCa33 and is associated with disease 
onset and progression34,35 was also reduced in VCaP cells upon treatment with the E43′ SSO 
(Fig. 3c). 
 Since we observed significant reductions in the proliferative capacity of SSO-treated 
VCaP cells, we next analysed whether SSO treatment also affected cell survival. We 
observed that reduced VCaP proliferation was mirrored by marked increases in levels of 
apoptosis following treatment with SSOs for 48-96 h (Fig. 3d), as determined by caspase-
3/7-positivity. We next we asked whether exon 4 SSOs affected VCaP cell migration. Using 
transwell chamber assays, we established that E43′ and E45′ SSO treatment significantly 
reduced the ability of VCaP cells to migrate through transwell membranes (Fig. 3e, 
Supplementary Fig. 2a). 
 ERG has been shown to drive the Wnt/β-catenin signalling in the context of PCa8,36. 
Since we observed that levels of the Wnt targets cyclin D137 and c-Myc38 were decreased by 
SSO treatment, we asked whether our ERG-targeting SSOs had an effect on Wnt/β-catenin 
signalling. Western blotting of SSO-treated VCaP cells revealed a reduction in Wnt/β-catenin 
signalling as indicated by a reduction in the level of the active upstream canonical LDL 
receptor LRP6 (p-LRP6) and the key Wnt transcriptional co-regulator β-catenin (Fig. 3f). We 
then confirmed that a significant reduction in migratory ability (Supplementary Fig. 2b) and 
Wnt/β-catenin signalling was also present in MG63 cells treated with the E43’ SSO (Fig. 3g). 
In addition, we also observed significant reductions in cyclin D1 and c-Myc protein levels in 
MG63s following treatment with the E43’ SSO (Supplementary Fig. 2c). Finally, we used 
TopFlash assays to directly measure Wnt/β-catenin signalling activity and observed a 
significant reduction in pathway activity in VCaP and MG63 cells treated with SSOs (Fig. 3h). 
Collectively these data suggest that the reduced ERG protein levels caused by SSOs reduce 
the tumorigenicity of PCa cells in vitro, and that this may be due in part to altered Wnt 
signalling.  
 
SSOs targeting ERG reduce tumour formation in vivo 
Since the E43′ SSO demonstrated more efficiency in vitro, and particularly in the context of 
MG63 cells, we sought to test the ability of this SSO to affect tumour progression in vivo. 
Using a xenograft model we subcutaneously injected 7 x 106 of the faster-growing ERG-
positive MG63 cells into nude mice and allowed tumours to establish to 3 mm x 3 mm. Mice 
were then administered with SSOs twice weekly by I.P. injection and tumour volumes were 
monitored over a period of 56 days. We observed that tumours from mice injected with the 
E43′ SSO were slower growing versus untreated and control tumours and significantly 
smaller in volume at several timepoints (Fig. 4a). E43′ SSO-treated tumours appeared 
smaller in size (Fig. 4b) and had reduced weight versus untreated tumours (Fig. 4d). We also 
saw a partial effect of the control SSO on tumour growth (Fig. 4a, b, d), suggesting a mild 
toxic or off-target effect, potentially due to the guanidinium mini-dendrimer present in the 
vivo-morpholinos; however, overall both SSOs appeared well tolerated by the mice (Fig. 4c), 
which was as expected, since we confirmed minimal complementarity between the mouse 
ERG gene and our E43′ SSO (Supplementary Fig. 3a). Furthermore, there were several E43′-
treated tumours with lower weights than in the control SSO mice (Fig. 4d, arrow) suggesting 
specific effects of the E43′ SSO on tumour growth. To confirm that this reduced tumour 
growth was due to effects of the E43′ SSO on ERG splicing and protein levels within the 
tumour, we harvested RNA and protein from treated tumours. RT-PCR revealed a small but 
significant increase in skipping of exon 4 in treated tumours (Fig. 4e). Moreover, western 
blotting indicated reduced levels of ERG protein in E43′ SSO-treated tumours versus 
untreated and control tumours (Fig. 4f), suggesting incorporation of the SSOs into tumours. 
We also confirmed that the E43′ SSO had no effects on endogenous endothelial ERG within 
the tumours by staining tumour sections with CD31 to assess blood vessel density 
(Supplementary Fig. 3b, c). Taken together, these data suggest the E43′ SSO is stable in vivo 
when delivered systemically, achieving efficient knockdown of ERG to reduce tumour 
growth. 
 
SSOs reduce ERG protein levels in patient-derived prostate cancer samples ex vivo 
The ability to target specific areas of tumour and benign tissue within radical prostatectomy 
specimens to produce high quality material for research purposes is becoming increasingly 
important for studies seeking to assess the efficacy of new therapeutic strategies. As such 
we employed the recently published PEOPLE method31 to obtain fresh radical 
prostatectomy specimens for ex vivo culture32. Here we tested the more efficacious E43′ 
SSO using fresh 6 mm cores from radical prostatectomy samples, which were grown on 
gelatin sponges (Supplementary Fig. 4a) and treated with SSOs. We obtained multiple cores 
from the tumours of five patients; however, we could only detect ERG expression in one of 
the samples designated PPL-0209 (Supplementary Fig. 4b, right panel). For PPL-0209, the 
patient had a PSA of 14.4 and from their MRI a Likert score of 4 was assigned. Patient age at 
surgery was 65 years and following a firm digital rectal exam all 9 cores of his transrectal 
ultrasound biopsy were positive for tumour with a Gleason score of G4+3 (Supplementary 
Fig. 4b, left panel). Clinical stage was T3bN1 and tumour volume was 13.67 ml. Interestingly, 
for cores obtained from this sample, treatment with the E43′ SSO for 24 h resulted in 
reduced ERG protein levels as assessed by western blotting when compared to untreated 
and scrambled control SSO samples (Supplementary Fig. 4c, d). We have previously 
demonstrated that ERG represses the transcription of the tumour suppressor gene PTEN in 
prostate cancer cells9. In support of this, in parallel to ERG reduction, we noted an increase 
in PTEN protein expression in the E43′ SSO-treated sample (Supplementary Fig. 4c, e). 
Although more patient samples and detailed further analyses of the consequences of this 
ERG reduction for tumour biology are required, this pilot data is an encouraging proof of 
principle for the use of SSOs to target ERG therapeutically in PCa. 
 
DISCUSSION 
ERG is commonly over-expressed in PCa (approximately 50-55% of cases), most often due to 
fusions with the androgen-responsive TMPRSS2 promoter6. ERG is considered a major driver 
of PCa and is thought to be responsible for many PCa cell traits4. Androgen deprivation 
therapy (ADT) is a widely used approach to prevent disease progression39. However, nearly 
all prostate cancers eventually become resistant to ADT40, meaning that there is a clinically 
unmet need for new therapies targeting the inappropriate activation of ERG due to 
TMPRSS2 fusions. Here we sought to test a novel approach using antisense morpholinos 
that cause exon skipping (SSOs) to disrupt pre-mRNA splicing of ERG to reduce ERG protein 
levels and mitigate oncogenic phenotypes driven by ERG. 
 We first designed SSOs targeting the 3′ and 5′ splice-sites of the constitutive exon 4 
of ERG, which we termed E43′ and E45′ respectively. We aimed to induce the skipping of 
exon 4 causing a frameshift and a resultant introduction of premature termination codons 
(PTCs) into the reading frame. We hypothesised that this approach would lead to NMD of 
ERG transcripts, thus offering a way to mitigate the over-expression of ERG seen in PCa. We 
found that both E43′ and E45′ SSOs were able to cause skipping of exon 4 as confirmed by 
RT-PCR and sequencing of PCR products, which demonstrated the absence of exon 4 
sequences in the smaller PCR product obtained from the SSO-treated ERG-positive PCa VCaP 
cell line, as well as the ERG-positive osteosarcoma MG63 cell line. Exon 4 skipping 
subsequently led to a reduction in ERG protein levels in VCaP and MG63 cells. ERG is 
thought to drive proliferation, survival, migration and invasion of PCa cells, and our current 
study supports this as in the VCaP cell line we observed that decreased ERG levels due to 
SSO treatment led to reduced cell proliferation, increased cell death and reduced cell 
migration. It has been established that ERG drives the oncogenic properties of PCa cells 
through Wnt/β-catenin activation and in line with this we saw reduced activation of the Wnt 
receptor LRP6 (p-LRP6) and reduced levels of the downstream executor of the pathway β-
catenin, alongside reduced expression of Wnt pathway genes cyclin D1 and c-Myc upon SSO 
transfection. Furthermore, TopFlash assays revealed reduced Wnt/β-catenin pathway 
activity. Interestingly, we observed differences in the efficacy of exon 4 skipping and 
resultant ERG reduction induced by the E43′ and E45′ SSOs. It is difficult to predict a priori 
how SSOs will interact with pre-mRNA structure, so it is possible that the E45′ SSO was less 
effective due to more limited access to the target sequence during splicing. Alternatively it 
may also be due to the E45′ SSO itself forming a secondary structure inhibiting its binding to 
the 5′ splice-site. Moreover, 5′ splice-site selection by the spliceosome is a complex process 
affected by many factors and there are many different consensus sequences possible that 
can act as a 5′ splice-site41, meaning that the steric blocking of the spliceosome at this site 
may not be as effective as expected. Of note, we have recently reported a similar 
phenomenon with SSOs targeting exon 7b of ERG, whereby SSOs targeting the 3′ splice-site 
were also more effective than those targeting the 5′ splice-site14. 
 Here we have also demonstrated the efficacy of targeting ERG with SSOs in vivo 
using xenograft models and ex vivo using patient-derived PCa tumour samples, supporting 
the approach of targeting an oncogene with SSOs, as others have also previously shown42,43. 
Mouse xenograft models using the ERG-positive MG63 cell line exhibited reduced tumour 
growth upon systemic E43′ SSO treatment, accompanied by reduced ERG protein levels in 
treated tumours harvested from the mice at the study’s conclusion. Importantly, the SSOs 
appeared well tolerated by the mice following systemic SSO delivery. In future, it will be 
necessary to ascertain any off-target effects at the molecular level in various organs such as 
the liver and kidneys where SSOs could become concentrated following intraperitoneal 
administration, as well as comprehensive analysis of SSO effects on tumour biology in vivo, 
and whether or not Wnt signalling is also disrupted in this context. Although the scrambled 
control SSO exhibited mildly-toxic or off-target effects on tumour growth, new less toxic in 
vivo delivery systems are currently being developed and should help to mitigate this in 
future studies. In a pilot ex vivo experiment we observed a substantial reduction in ERG 
protein level and a concomitant increase in PTEN protein level in a primary PCa patient 
sample treated with the E43′ SSO. These results will need to be supplemented by further 
studies on larger numbers of PCa patient samples as well as detailed analysis of the effects 
of ERG knockdown on the cell biology and signalling within patient-derived tumours. Finally, 
as well as providing a new potential therapeutic approach for the treatment of PCa patients, 
since ERG rearrangements and fusions are also present in Ewing’s sarcoma44 and in acute 
myeloid leukemia45, and no doubt in other neoplasms, the use of SSOs to target ERG may be 
a suitable therapeutic approach in several cancer types. 
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FIGURE LEGENDS 
 
Fig. 1 Validation of splice-switching oligonucleotides targeting ERG exon 4 in VCaP cells. a 
Schematic showing targeting of ERG exon 4 (E4) with splice-switching oligonucleotides 
(SSOs) designed against the 3′ (E43′) or 5′ (E45′) splice sites (see Supplementary Fig. 1a for 
additional SSO sequence details). Skipping of exon 4 is denoted by the dashed line. PCR 
primers to detect the presence or absence of exon 4 are indicated (2F and 6R). b 
Quantification of dose-dependent exon 4 skipping in VCaP cells treated with E4 SSOs for 24 
h (n = 3, except for ctrl SSO at 6 µM, n = 2). A representative RT-PCR of exon 4 skipping is 
shown on the right. c Representative RT-PCR panels showing exon 4 skipping after 24-72 h 
treatment of VCaP cells with 8 µM E4 SSOs. d Quantifications of exon 4 skipping in VCaP 
cells treated with 8 µM E4 SSOs for 24-72 h (n = 3 at all timepoints). *** = p<0.001, ** = 
p<0.01, * = p<0.05. Ctrl SSO: control SSO. 
 
Fig. 2 Splice-switching caused by ERG exon 4 SSOs reduces ERG protein levels in two cancer 
cell lines. a Representative ERG and GAPDH (loading control) western blots of lysates from 
VCaP cells treated with 8 µM SSOs for 24 h, 72 h and 96 h. The arrowhead indicates a 
putative truncated ERG isoform (full length is 54kD). b Quantifications of ERG western blots 
from VCaP cells treated with SSOs for 24-96 h (n = 4 for 24 h and 72 h, n = 3 for 96 h, except 
for ctrl SSO at 96 h, n = 2). c Representative RT-PCR panels for MG63 cells treated with 1 µM 
or 3 µM for 24 h. d Quantification of exon 4 skipping in MG63 cells treated with SSOs at 1 
µM or 3 µM for 24 h (n = 3). e Representative ERG and β-actin (loading control) western 
blots of lysates from MG63 cells treated with SSOs for 48 h and 72 h. The arrow indicates 
full-length ERG isoform (54kD) and arrowhead indicates truncated ERG isoform. f 
Quantifications of ERG western blots from MG63 cells treated with 5 µM SSOs for 48 h and 
72 h (n = 8 for untreated and ctrl SSO, for E43′ n = 4 at 48 h; n = 6 at 72 h). ERG protein 
expression levels were normalised to GAPDH. *** = p<0.001, ** = p<0.01, * = p<0.05. Ctrl 
SSO: control SSO. 
 
Fig. 3 ERG exon 4 SSOs affect VCaP cancer cell behaviour and signalling. a Representative 
immunofluorescence images for Ki67 (grey) and Hoechst (blue) after 48 h of 8 µM E4 SSO 
treatment in VCaP cells. b Quantification of Ki67+ VCaP cells after 48-96 h of 8 µM E4 SSO 
treatment (n = 3 for all time points). c Western blotting and quantification for regulators of 
cell cycle progression, cyclin D1 and c-Myc, following 72 h of 8 µM E4 SSO treatment in VCaP 
cells (n = 3). β-actin was used as loading control. d Caspase-3/7 staining of VCaP cells 
treated with E4 SSOs at 8 µM for 48 h and 96 h (n = 3 at all timepoints). e Quantification of 
VCaP cells migrated in transwell assays after 48 h of E4 SSO treatment at 8 µM (n = 4, except 
for untreated where n = 3). f and g Representative western blotting for and quantification of 
key components of the canonical Wnt signaling pathway (β-catenin and p-LRP6) following 
72 h of SSO treatment in VCaP cells (8 µM) and MG63 (3 µM) cells respectively (n = 3). β-
actin was used as loading control. h TopFlash assays to assess Wnt pathway activity 
following 72 h of SSO treatment in VCaP cells and MG63 cells.  *** = p<0.001, ** = p<0.01, * 
= p<0.05. Unt: untreated; Ctrl SSO: control SSO. Scale bar = 40 µm. 
Fig. 4 ERG exon 4 SSOs have anti-tumour effects in vivo. a Subcutaneous tumour growth of 
the ERG+ MG63 cell line was measured twice weekly following IP injection of E43′ SSOs. 
Tumour measurements and dosing were performed on the same day. b Representative 
images of subcutaneous tumours (indicated by highlighted regions) in situ. c Measurements 
of body weight following systemic administration of SSOs. d Endpoint tumour weights from 
mice treated with SSOs (n = 8 for untreated; n = 11 for scrambled ctrl SSO; n = 10 for E43′ 
SSO). e Representative RT-PCR panels (left) and quantifications (right) of exon 4 skipping 
(arrow) from tumour tissue extracted at endpoints (n = 5 for untreated; n = 7 for scrambled 
ctrl and E43′ SSOs). f Representative panels for ERG and GAPDH (loading control) western 
blotting (left) in tumour tissue extracted from mice at endpoints. Quantification of ERG 
western blotting in tumours shown on right (n = 3 for untreated; n = 7 for scrambled ctrl 
SSO; n = 8 for E43′ SSO). ERG protein expression levels were normalised to GAPDH.  *** = 
p<0.001, ** = p<0.01, * = p<0.05. Scr ctrl SSO: Scrambled control SSO. 
 
REFERENCES 
 
1 Meadows, S.M., Myers, C.T., Krieg, P.A. Regulation of endothelial cell development by 
ETS transcription factors. Sem. Cell Dev. Biol. 22, 976-984 (2011). 
2 Werner, M.H. et al. The solution structure of the human ETS1-DNA complex reveals a 
novel mode of binding and true side chain intercalation. Cell 83, 761-771 (1995). 
3 Rao, V.N., Papas, T.S., Reddy, E.  ERG, a human ets-related gene on chromosome 21: 
alternative splicing, polyadenylation, and translation. Science  237, 635-639 (1987). 
4 Adamo, P., Ladomery, M.R. The oncogene ERG: a key factor in prostate cancer. 
Oncogene 35, 403-414 (2015). 
5 Rosen, P., Sesterhenn, I.A., Brassell, S.A., McLeod, D.G., Srivastava, S., Dobi, A. Clinical 
potential of the ERG oncoprotein in prostate cancer. Nat. Rev. Urol. 10, 483-487 (2012). 
6 Tomlins, S.A.  et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in 
prostate cancer. Science 310, 644-648 (2005). 
7 Hagen, R.M. et al. Quantitative analysis of ERG expression and its splice isoforms in 
formalin fixed, paraffin-embedded prostate cancer samples: association with seminal 
vesicle invasion and biochemical recurrence. Am. J .Clin. Pathol. 142, 533-540 (2014). 
8 Chakravarthi, B.,V.,S.,K., et al. Wnt receptor Frizzled 8 is a target of ERG in prostate 
cancer. Prostate 78, 1311-1320 (2018). 
9 Adamo, P. et al. The oncogenic transcription factor ERG represses the transcription of 
the tumour suppressor gene PTEN in prostate cancer cells. Oncol. Lett. 14, 5605-5610 
(2017). 
10 Zhou, F. et al. TMPRSS2-ERG activates NO-cGMP signalling in prostate cancer cells. 
Oncogene Feb 4 Epub ahead of print (2019). 
11 Delliaux, C. et al. TMPRSS2:ERG gene fusion expression regulates bone markers and 
enhances the osteoblastic phenotype of prostate cancer bone metastases. Cancer Lett. 
438, 32-43 (2018). 
12 Shan, L., Ji, T., Su, X., Shao, Q., Du, T., Zhang, S. TMPRSS2-ERG fusion promotes 
recruitment of regulatory T cells and tumor growth in prostate cancer. Am. J. Med. Sci. 
356, 72-78 (2018). 
13 Salek-Ardakani, S. et al. ERG is a megakaryocytic oncogene. Cancer Res. 69, 4665-4673 
(2009). 
14 Jumbe, S. et al. The evolutionarily conserved cassette exon 7b drives ERG’s oncogenic 
properties. Transl. Oncol. 12, 134-142 (2019). 
15 Kedage, V. et al. Phosphorylation of the oncogenic transcription factor ERG in prostate 
cells dissociates polycomb repressive complex 2, allowing target gene activation. J. Biol. 
Chem. 292, 17225-17235 (2017). 
16 Wang, J., Cai, Y., Yu, W., Ren, C., Spencer, D.M., Ittmann, M. Pleiotropic biological 
activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 68, 
8516-8524 (2008). 
17 Brenner, J.C. et al. Mechanistic rationale for inhibition of poly (ADP-ribose) polymerase 
in ETS gene fusion positive prostate cancer. Cancer Cell 19, 664-678 (2011). 
18 Chatterjee, P. et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG 
fusion gene expressing and PTEN-deficient prostate cancer cells. PLoS One 8, e60408 
(2013). 
19 Björkman, M., Iljin, K. et al. Defining the molecular action of HDAC inhibitors and 
synergism with androgen deprivation in ERG‐positive prostate cancer. Int. J. Cancer 
123, 2774-2781 (2008). 
20 Lambert, M., Jambon, S., Depauw S., David-Cordonnier, M-H. Targeting transcription 
factors for cancer treatment. Molecules 23, 1479 (2018). 
21 Rahim, S., Beauchamp, E.M., Kong, Y., Brown, M.L., Toretsky, J.A., Üren, A. YK-4-279 
inhibits ER and ETV1 mediated prostate cancer cell invasion. Plos One 6, e19343 (2011). 
22 Winters, B. et al. Inhibition of ERG activity in patient-derived prostate cancer xenografts 
by YK-4-279. Anticancer Res. 37, 3385-3396 (2017). 
23 Castanotto, D., Stein, C.A. Antisense oligonucleotides in cancer. Curr. Opin. Oncol. 26, 
584-589 (2014). 
24 Le, B.T., Raguraman, P., Kosbar, T.R., Fletcher, S., Wilton, S.D., Veedu, R.N. Antisense 
oligonucleotides targeting angiogenic factors as potential cancer therapeutics. Mol. 
Ther. Nucleic Acids 14, 142-157 (2019). 
25 Oberemok, V.V. et al. A half-century history of applications of antisense 
oligonucleotides in medicine, agriculture and forestry: we should continue the journey. 
Molecules 29, E1302 (2018). 
26 Summerton, J.E. Invention and early history of morpholinos: from pipe dream to 
practical products. Methods Mol. Biol 1565, 1-15 (2017). 
27 Charleston, J.S. et al. Eteplirsen treatment for Duchenne muscular dystrophy: exon 
skipping and dystrophin production. Neurology 90, e2146 (2018). 
28 Bauman, J., Jearawiriyapaisarn, N., Kole, R. Therapeutic potential of splice-switching 
oligonucleotides. Oligonucleotides 19, 1-13 (2009) 
29 Smith, L.D. et al. A targeted oligonucleotide enhancer of SMN2 exon 7 splicing forms 
competing quadruplex and protein complexes in functional conditions. Cell Rep. 9, 193-
205 (2014). 
30 Neil, E. E., Bisaccia, E. K. Nusinersen: a novel antisense oligonucleotide for the 
treatment of Spinal Muscular Atrophy. J. Pediatr. Pharmacol. Ther. 24, 194-203 (2019). 
31 Heavey, S. et al. PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection 
pathway utilizing magnetic resonance imaging data to target tumor and benign tissue in 
fresh radical prostatectomy specimens. Prostate 79, 768-777 (2019). 
32 Centenera, M.M. et al. Ex vivo culture of human prostate tissue and drug development. 
Nat. Rev. Urol. 10, 483–487 (2013). 
33 Akinyeke, T. et al. Metformin targets c-MYC oncogene to prevent prostate cancer. 
Carcinogenesis 34, 2823-2832 (2013). 
34 Sun, C. et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer 
activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27, 5348-
5353 (2008). 
35 Zeng, W. et al. Nuclear C-MYC expression level is associated with disease progression 
and potentially predictive of two year overall survival in prostate cancer. Int. J. Clin. Exp. 
Pathol. 8, 1878-1888 (2015). 
36 Wu, L., Zhao, J.C., Kim, J., Jin, H.J., Wnag, C.Y., Yu, J. ERG is a critical regulator of 
Wnt/LEF1 signaling in prostate cancer. Cancer Res. 73, 6068-79 (2013). 
37 Shtutman, M. et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. 
Proc. Natl. Acad. Sci USA 96, 5522-5527 (1999). 
38 Shang, S., Hua, F., Hu, Z.W. The regulation of β-catenin activity and function in cancer: 
therapeutic opportunities. Oncotarget 8, 33972-33989 (2017). 
39 Crook, J.M. et al. Intermittent androgen suppression for rising PSA level after 
radiotherapy. N. Engl. J. Med. 367, 895-903 (2012). 
40 Anantharaman, A., Small, E.J. Tackling non-metastatic castration-resistant prostate 
cancer: special considerations in treatment. Expert Rev. Anticancer Ther. 17, 625-633 
(2017).  
41 Roca, X., Krainer, A.R., Eperon, I.C. Pick one, but be quick: 5' splice sites and the 
problems of too many choices. Genes Dev. 27, 129-144 (2013). 
42 Wan, J., Sazani, P., Kole, R. Modification of HER2 pre-mRNA alternative splicing and its 
effects on breast cancer cells. International Journal of Cancer 124, 772-777 (2009). 
43 Kralovicova, J., Knut, M., Cross, N.C.P., Vorechovsky, I. Exon-centric regulation of ATM 
expression is population-dependent and amenable to antisense modification by 
pseudoexon targeting. Sci. Rep. 6, 18741 (2016). 
44 Chen, S., Deniz, K., Sung, Y.S., Zhang, L., Dry, S., Antonescu, C.R. Ewing sarcoma with 
ERG gene rearrangements: A molecular study focusing on the prevalence of FUS-ERG 
and common pitfalls in detecting EWSR1-ERG fusions by FISH. Genes Chromosomes 
Cancer 55, 340-349 (2016). 
45 Sotoca, A.M. The oncofusion protein FUS-ERG targets key hematopoietic regulators and 
modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid 
leukemia. Oncogene 35, 1965-1976 (2016). 




